Compositions containing arginase 1 for the treatment of neurovascular and retinal vascular disorders
AssigneeAugusta University Research Institute, Inc.
InventorRuth CALDWELL
Life of this patent
Estimating the term…
Abstract
Pathological retinal neovascularization is a common micro-vascular complication in several retinal diseases including retinopathy of prematurity (ROP), diabetic retinopathy, age-related macular degeneration and central vein occlusion. Disclosed herein are compositions and methods useful for the treatment or prevention of retinal neovascularization and related diseases in a subject in need thereof. Exemplary methods include administering a composition including PEGylated arginase 1 to a subject in need thereof to promote reparative angiogenesis and decrease retinal neovascularization in the eye.
Claims29
A method of inducing or promoting the regression of retinal neovascularization induced injury in a subject in need thereof, comprising administering to the eye of the subject a composition comprising recombinant arginase 1 in an amount effective to promote reparative angiogenesis and decrease retinal neovascularization in the eye to induce or promote the regression of retinal neovasculariation.
A method of reducing or inhibiting the progression of retinal neovascularization related disease in a subject in need thereof, comprising administering to the subject a composition comprising recombinant arginase 1 in an amount effective to promote reparative angiogenesis and decrease retinal neovascularization in the eye.
A method of treating retinopathy of prematurity in an infant in need thereof, comprising administering to the infant a composition comprising recombinant arginase 1 in an amount effective to promote reparative angiogenesis and decrease retinal neovascularization in the eye to induce or promote the regression of retinal neovasculariation.
An ophthalmic composition comprising pegylated arginase 1.
A method of preventing or treating neurodegeneration in a subject in need thereof, comprising administering to the subject a composition comprising recombinant arginase 1 in an amount effective to promote neuroprotection or neurogenesis.
Dependencies are inferred from the claim text.